Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Follow-Up Questions
Who is the CEO of Ginkgo Bioworks Holdings Inc?
Dr. Jason Kelly is the Chief Executive Officer of Ginkgo Bioworks Holdings Inc, joining the firm since 2021.
What is the price performance of DNA stock?
The current price of DNA is $11.68, it has decreased 8.67% in the last trading day.
What are the primary business themes or industries for Ginkgo Bioworks Holdings Inc?
Ginkgo Bioworks Holdings Inc belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is Ginkgo Bioworks Holdings Inc market cap?
Ginkgo Bioworks Holdings Inc's current market cap is $656.4M
Is Ginkgo Bioworks Holdings Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Ginkgo Bioworks Holdings Inc, including 0 strong buy, 1 buy, 2 hold, 5 sell, and 0 strong sell
